FDA Gives Designations to Hemophilia Gene Therapies – Pharmacy Practice News
Pharmacy Practice News |
FDA Gives Designations to Hemophilia Gene Therapies
Pharmacy Practice News Within the past week, the FDA has awarded special designations to two new gene therapy candidates for hemophilia. On Oct. 25, the FDA granted orphan drug designation and investigational new drug (IND) status to an investigational factor VIII (FVIII … With 'breakthrough' status and a handy nickname, BioMarin plots … BioMarin's Gene Therapy for Hemophilia A Continues to Impress Breakthrough status for BioMarin ratchets up haemophilia A … |
